Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Gets FDA OK for H1N1 Info in Package Insert for Assay

NEW YORK (GenomeWeb News) – Nanosphere today said that the US Food and Drug Administration has granted the firm 510(k) clearance to update the package insert for its Verigene Respiratory Virus Nucleic Acid Test to include reactivity with Influenza A in cultured clinical isolates containing 2009 H1N1 influenza virus.

The Northbrook, Ill.-based molecular diagnostics firm said that its tests had confirmed that the Verigene assay, which was cleared by FDA last month, correctly identifies Influenza A in cultured clinical isolates containing 2009 H1N1.

"Although the [assay] has been shown to detect the 2009 H1N1 influenza virus in cultured isolates, the performance characteristics of this device with patient specimens that are positive for the 2009 H1N1 influenza virus have not been established," Nanosphere said in a statement. It added that the assay can distinguish between Influenza A and B viruses, but it does not differentiate influenza subtypes.

Last month, the FDA cleared the Verigene Respiratory Virus Nucleic Acid Test to run on the firm's new Verigene SP system for the differential diagnosis of Influenza A, Influenza B, and RSV infections.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.